Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
On January 6 and seven, Ryan J. Watts, the President and CEO of Denali Therapeutics Inc. (NASDAQ:DNLI), a $3.05 billion market cap biotech firm, executed a sequence of inventory gross sales totaling $750,955. The transactions concerned the sale of 29,266 shares at a mean worth of $20.22 on January 6, and an extra 7,650 shares at $20.81 on January 7. In accordance with InvestingPro knowledge, analysts keep a Robust Purchase consensus on the inventory, which at the moment seems undervalued primarily based on Truthful Worth evaluation.
These gross sales have been made to fulfill tax obligations associated to the settlement of beforehand vested restricted inventory models. Following these transactions, Watts holds 253,071 shares straight, which embrace 177,940 unvested restricted inventory models. Moreover, he has oblique possession of two,202,604 shares by the Watts Household 2015 Belief. InvestingPro evaluation reveals the corporate maintains sturdy monetary well being with extra cash than debt and a robust present ratio of 9.98. Subscribers can entry 6 further ProTips and complete monetary metrics at InvestingPro.
In different latest information, Denali Therapeutics has had vital developments. The U.S. Meals and Drug Administration (FDA) granted Breakthrough Remedy Designation to Denali’s DNL310 for the therapy of Hunter Syndrome. The corporate plans to file a Biologics License Utility for accelerated approval in 2025. Analysts from Stifel, Jefferies, H.C. Wainwright, BofA Securities, and Baird have maintained Purchase scores on Denali, with various worth targets.
Regardless of the failure of the Part II/III HEALEY trial for ALS therapy DNL343 to fulfill its main endpoint, analysts stay optimistic about Denali’s prospects, notably on account of its Transport Vesicle platform and the promising prospects of Tividenofusp alfa. The corporate’s monetary place stays sturdy, with a present ratio of 9.98 and extra cash than debt on its stability sheet.
These are latest developments, reflecting Denali’s ongoing efforts in drug improvement, its interactions with the FDA, and its monetary well being. The corporate’s subsequent earnings report is scheduled for March 3, 2025, which is anticipated to supply traders with extra readability on the corporate’s progress. These insights are primarily based on the evaluation of assorted analysts and the corporate’s latest bulletins.
This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.
